tazobactam has been researched along with pindolol in 1 studies
| Studies (tazobactam) | Trials (tazobactam) | Recent Studies (post-2010) (tazobactam) | Studies (pindolol) | Trials (pindolol) | Recent Studies (post-2010) (pindolol) |
|---|---|---|---|---|---|
| 1,327 | 153 | 694 | 3,718 | 662 | 92 |
| Protein | Taxonomy | tazobactam (IC50) | pindolol (IC50) |
|---|---|---|---|
| Beta-2 adrenergic receptor | Homo sapiens (human) | 0.0005 | |
| Beta-1 adrenergic receptor | Homo sapiens (human) | 0.0009 | |
| Beta-3 adrenergic receptor | Homo sapiens (human) | 0.088 | |
| 5-hydroxytryptamine receptor 1A | Rattus norvegicus (Norway rat) | 0.048 | |
| 5-hydroxytryptamine receptor 1B | Rattus norvegicus (Norway rat) | 0.048 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Choi, SS; Contrera, JF; Hastings, KL; Kruhlak, NL; Sancilio, LF; Weaver, JL; Willard, JM | 1 |
1 other study(ies) available for tazobactam and pindolol
| Article | Year |
|---|---|
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Topics: | 2008 |